Assessing and Managing Primary Hyperparathyroidism and Fracture Risk in England: A Survey of Medical Professionals
- PMID: 39876875
- PMCID: PMC11772554
- DOI: 10.1210/jendso/bvae225
Assessing and Managing Primary Hyperparathyroidism and Fracture Risk in England: A Survey of Medical Professionals
Abstract
Purpose: To describe diagnostic approaches and management strategies for patients with primary hyperparathyroidism (PHPT) and recent fracture in England.
Methods: We developed a survey based on a patient at high fracture risk and a new diagnosis of probable PHPT. The survey was circulated among 50 secondary care professionals identified by the Society for Endocrinology Calcium and Bone special interest group. Descriptive statistics, combinatorial, and thematic analyses were employed.
Results: In the patient with hyperparathyroidism and a recent fracture, 54% of respondents favoured a 24-hour urinary calcium: creatinine clearance ratio, with 85% opting to do so after correcting vitamin D levels. Thirty-two percent (16/50) preferred the spot urinary calcium:creatinine clearance ratio, as a random test (56%, n = 9/16). Ninety-six percent of the respondents agreed they would include a fracture risk assessment in their management plan. Eighty-five percent of the respondents selected dual-energy X-ray absorptiometry scans of the lumbar spine, total hip, and femoral neck as the most popular choice. Before initiating antiosteoporotic medications (AOMs), 94% of the respondents preferred correcting vitamin D levels with diverse regimens. IV zoledronate acid was the preferred AOM, and 58% (n = 29/50) supported cinacalcet usage if the patient was ineligible for parathyroid surgery, while 26% (n = 13/50) opposed cinacalcet use entirely. No significant correlation was found between status as an endocrinology consultant or working in a tertiary care hospital and these management preferences.
Main conclusion: This study of National Health Service medical staff identified highly-varied clinical practices in managing PHPT in the setting of high fracture risk, highlighting the need for pragmatic guidelines and wider education.
Keywords: antiosteoporotic medication; fracture; hyperparathyroidism; survey.
© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society.
Figures
Similar articles
-
Clinical, Biochemical, and Radiological Profile of Normocalcemic Primary Hyperparathyroidism.J Clin Endocrinol Metab. 2020 Jul 1;105(7):dgaa174. doi: 10.1210/clinem/dgaa174. J Clin Endocrinol Metab. 2020. PMID: 32271382
-
The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.J Bone Miner Res. 2022 Nov;37(11):2351-2372. doi: 10.1002/jbmr.4685. Epub 2022 Oct 17. J Bone Miner Res. 2022. PMID: 36053960
-
Phalangeal quantitative ultrasound technology and dual energy X-ray densitometry in patients with primary hyperparathyroidism: influence of sex and menopausal status.Osteoporos Int. 2003 Jul;14(7):602-8. doi: 10.1007/s00198-003-1407-2. Epub 2003 Apr 29. Osteoporos Int. 2003. PMID: 12730752
-
[Primary hyperparathyroidism: new concepts, new recommendations].Ann Endocrinol (Paris). 2014 Oct;75 Suppl 1:S21-36. doi: 10.1016/S0003-4266(14)70024-1. Ann Endocrinol (Paris). 2014. PMID: 25617920 French.
-
Management of skeletal health in patients with asymptomatic primary hyperparathyroidism.J Clin Densitom. 2010 Oct-Dec;13(4):324-34. doi: 10.1016/j.jocd.2010.06.004. J Clin Densitom. 2010. PMID: 21029971 Review.
Cited by
-
Estimated fracture risk in osteopenic patients with primary hyperparathyroidism.Endocrine. 2025 Sep 10. doi: 10.1007/s12020-025-04406-5. Online ahead of print. Endocrine. 2025. PMID: 40928688
References
-
- Cope O. The story of hyperparathyroidism at the Massachusetts general hospital. N Engl J Med. 1966;274(21):1174‐1182. - PubMed
LinkOut - more resources
Full Text Sources